THERMOCOOL SMARTTOUCH SF (Uni-Directional and Bi-Directional)/DUAL ENERGYTHERMOCOOL SMARTTOUCH SF CATHETERS
Biosense Webster, Inc. · Decision date Jun 10, 2026
What did the FDA decide?
FDA records P030031/S144 as a supplement to PMA P030031, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 10, 2026.
FDA approval order statement
an additional supplier for critical components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 10, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P030031/S144
- Regulatory pathway
- PMA supplement
- Applicant
- Biosense Webster, Inc.
- Product code
- OAD
- Decision code
- OK30
- Decision date
- Jun 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.
- Applicant
- Biosense Webster, Inc.
- Product code
- OAD
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P030031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030031 · Original PMA
BIOSENSE WEBSTER NAVISTAR/CELSIUS THERMO COOL DIAGNOSTIC/ABLATION DEFLECTABLE TIP CATHETERS
P030031/S144 received
Application receipt date recorded by FDA.
P030031/S144 · FDA decision
30-Day Notice
P030031/S143 · Related supplement
VISITAG SURPOINT External Processing Unit (EPU); CARTO 3 System
P030031/S141 · Related supplement
Dual Energy THERMOCOOL SMARTTOUCH SF System
P030031/S142 · Related supplement
THERMOCOOL SMARTTOUCH SF Catheter
P030031/S146 · Related supplement
EZ STEER THERMOCOOL NAV BI-DIRECTIONAL ELECTROPHYSIOLOGY CATHETER; THERMOCOOL SMARTTOUCH BI-DIRECTIONAL NAVIGATION CATHE
Timeline entries are records held by MedtechLedger for P030031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA approval | Nov 5, 2004 | FDA | |
| Biosense Webster, Inc. | PMA supplement | Jun 30, 2026 | FDA | |
Dual Energy THERMOCOOL SMARTTOUCH SF SystemP030031/S141 | Biosense Webster, Inc. | PMA supplement | Jul 1, 2026 | FDA |
THERMOCOOL SMARTTOUCH SF CatheterP030031/S142 | Biosense Webster, Inc. | PMA supplement | Sep 2, 2026 | FDA |
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Explore the linked device profile
Other records with product code OAD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Therapy Dual-8 Ablation CatheterP040042/S060 | Irvine Biomedical,Inc.(Ibi) | PMA supplement | Sep 3, 2026 | FDA |
Ampere GeneratorP040042/S059 | Irvine Biomedical,Inc.(Ibi) | PMA supplement | Aug 7, 2026 | FDA |
Ampere GeneratorP060019/S059 | Irvine Biomedical, Inc. | PMA supplement | Aug 7, 2026 | FDA |
Ampere GeneratorP110016/S095 | ABBOTT MEDICAL | PMA supplement | Aug 7, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Jun 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P030031/S144
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



